Deletion in exon 5 of the SNCA gene and exposure to rotenone leads to oligomerization of α-synuclein and toxicity to PC12 cells

Brain Research Bulletin

Volumn 90, Issue 1, 2013, Pages 127-131

  Ma, Kai Li ^a,b   Song, Lian Kun ^a   Long, Whitney Annie ^a   Yuan, Yu He ^a   Zhang, Ying ^b   Song, Xiu Yun ^a   Niu, Fei ^a   Han, Ning ^a   Chen, Nai Hong ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b INSTITUTE OF MEDICAL BIOLOGY   (China)

Author keywords

Synuclein; Oligomerization; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; COMPLEMENTARY DNA; ROTENONE; SNCA PROTEIN; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ARTICLE; CELL CULTURE; CELL STRAIN; CELL VIABILITY; CYTOTOXICITY; EXON; GENE AMPLIFICATION; GENE DELETION; GENE OVEREXPRESSION; OLIGOMERIZATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ALPHA-SYNUCLEIN; ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; EXONS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; INSECTICIDES; MODELS, MOLECULAR; PC12 CELLS; PROTEIN ISOFORMS; RATS; ROTENONE; SEQUENCE DELETION; TRANSFECTION;

EID: 84870552532     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2012.10.007     Document Type: Article

References (45)

1. Ahmadi F.A., Linseman D.A., Grammatopoulos T.N., Jones S.M., Bouchard R.J., Freed C.R., Heidenreich K.A., Zawada W.M. The pesticide rotenone induces caspase-3-mediated apoptosis in ventral mesencephalic dopaminergic neurons. Journal of Neurochemistry 2003, 87:914-921.
2. Albani D., Peverelli E., Rametta R., Batelli S., Veschini L., Negro A., Forloni G. Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70. FASEB Journal 2004, 18:1713-1715.
3. Badiola N., de Oliveira R.M., Herrera F., Guardia-Laguarta C., Goncalves S.A., Pera M., Suarez-Calvet M., Clarimon J., Outeiro T.F., Lleo A. Tau enhances alpha-synuclein aggregation and toxicity in cellular models of synucleinopathy. PLoS One 2011, 6:e26609.
4. Beyer K. Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathologica 2006, 112:237-251.
5. Beyer K., Domingo-Sabat M., Humbert J., Carrato C., Ferrer I., Ariza A. Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease. Neurogenetics 2008, 9:163-172.
6. Beyer K., Domingo-Sabat M., Lao J.I., Carrato C., Ferrer I., Ariza A. Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases. Neurogenetics 2008, 9:15-23.
7. Beyer K., Humbert J., Ferrer A., Lao J.I., Carrato C., Lopez D., Ferrer I., Ariza A. Low alpha-synuclein 126 mRNA levels in dementia with Lewy bodies and Alzheimer disease. Neuroreport 2006, 17:1327-1330.
8. Beyer K., Lao J.I., Carrato C., Mate J.L., Lopez D., Ferrer I., Ariza A. Differential expression of alpha-synuclein isoforms in dementia with Lewy bodies. Neuropathology and Applied Neurobiology 2004, 30:601-607.
9. Beyer K., Lao J.I., Carrato C., Mate J.L., Lopez D., Ferrer I., Ariza A. Upregulation of amyloid precursor protein isoforms containing Kunitz protease inhibitor in dementia with Lewy bodies. Brain Research: Molecular Brain Research 2004, 131:131-135.
10. Britton F.C., Wang G.L., Huang Z.M., Ye L., Horowitz B., Hume J.R., Duan D. Functional characterization of novel alternatively spliced ClC-2 chloride channel variants in the heart. The Journal of Biological Chemistry 2005, 280:25871-25880.
11. Campion D., Martin C., Heilig R., Charbonnier F., Moreau V., Flaman J.M., Petit J.L., Hannequin D., Brice A., Frebourg T. The NACP/synuclein gene: chromosomal assignment and screening for alterations in Alzheimer disease. Genomics 1995, 26:254-257.
12. Caughey B., Lansbury P.T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annual Review of Neuroscience 2003, 26:267-298.
13. Conway K.A., Harper J.D., Lansbury P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nature Medicine 1998, 4:1318-1320.
14. Conway K.A., Harper J.D., Lansbury P.T. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 2000, 39:2552-2563.
15. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Harper J.D., Williamson R.E., Lansbury P.T. Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants. Annals of the New York Academy of Sciences 2000, 920:42-45.
16. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., Lansbury P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:571-576.
17. Crowther R.A., Jakes R., Spillantini M.G., Goedert M. Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Letters 1998, 436:309-312.
18. Danzer K.M., Haasen D., Karow A.R., Moussaud S., Habeck M., Giese A., Kretzschmar H., Hengerer B., Kostka M. Different species of alpha-synuclein oligomers induce calcium influx and seeding. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2007, 27:9220-9232.
19. Dawson T.M., Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003, 302:819-822.
20. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M.S., Shen J., Takio K., Iwatsubo T. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nature Cell Biology 2002, 4:160-164.
21. Ischiropoulos H., Beckman J.S. Oxidative stress and nitration in neurodegeneration: cause, effect, or association. The Journal of Clinical Investigation 2003, 111:163-169.
22. Karpinar D.P., Balija M.B., Kugler S., Opazo F., Rezaei-Ghaleh N., Wender N., Kim H.Y., Taschenberger G., Falkenburger B.H., Heise H., Kumar A., Riedel D., Fichtner L., Voigt A., Braus G.H., Giller K., Becker S., Herzig A., Baldus M., Jackle H., Eimer S., Schulz J.B., Griesinger C., Zweckstetter M. Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO Journal 2009, 28:3256-3268.
23. Lee H.J., Choi C., Lee S.J. Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. The Journal of Biological Chemistry 2002, 277:671-678.
24. Li W., West N., Colla E., Pletnikova O., Troncoso J.C., Marsh L., Dawson T.M., Jakala P., Hartmann T., Price D.L., Lee M.K. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:2162-2167.
25. Ma K.L., Yuan Y.H., Song L.K., Han N., Chen N.H. Over-expression of alpha-synuclein 98 triggers intracellular oxidative stress and enhances susceptibility to rotenone. Neuroscience Letters 2011, 491:148-152.
26. Mazzulli J.R., Armakola M., Dumoulin M., Parastatidis I., Ischiropoulos H. Cellular oligomerization of alpha-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence. The Journal of Biological Chemistry 2007, 282:31621-31630.
27. McCarthy J.J., Linnertz C., Saucier L., Burke J.R., Hulette C.M., Welsh-Bohmer K.A., Chiba-Falek O. The effect of SNCA 3' region on the levels of SNCA-112 splicing variant. Neurogenetics 2011, 12:59-64.
28. Moon Y., Lee K.H., Park J.H., Geum D., Kim K. Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: protective effect of coenzyme Q10. Journal of Neurochemistry 2005, 93:1199-1208.
29. Murray I.V., Giasson B.I., Quinn S.M., Koppaka V., Axelsen P.H., Ischiropoulos H., Trojanowski J.Q., Lee V.M. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 2003, 42:8530-8540.
30. Narhi L., Wood S.J., Steavenson S., Jiang Y., Wu G.M., Anafi D., Kaufman S.A., Martin F., Sitney K., Denis P., Louis J.C., Wypych J., Biere A.L., Citron M. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. The Journal of Biological Chemistry 1999, 274:9843-9846.
31. Outeiro T.F., Putcha P., Tetzlaff J.E., Spoelgen R., Koker M., Carvalho F., Hyman B.T., McLean P.J. Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One 2008, 3:e1867.
32. Pan D.N., Li J.J., Wei L., Yao M., Wan D.F., Gu J.R. Inhibitory effect of CT120B, an alternative splice variant of CT120A, on lung cancer cell growth. Acta Biochimica et Biophysica Sinica 2005, 37:588-592.
33. Radad K., Rausch W.D., Gille G. Rotenone induces cell death in primary dopaminergic culture by increasing ROS production and inhibiting mitochondrial respiration. Neurochemistry International 2006, 49:379-386.
34. Recchia A., Debetto P., Negro A., Guidolin D., Skaper S.D., Giusti P. Alpha-synuclein Parkinson's disease. FASEB Journal 2004, 18:617-626.
35. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Journal of Neurochemistry 1990, 54:823-827.
36. Schapira A.H., Cooper J.M., Dexter D., Jenner P., Clark J.B., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989, 1:1269.
37. Serpell L.C., Berriman J., Jakes R., Goedert M., Crowther R.A. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:4897-4902.
38. Sherer T.B., Betarbet R., Stout A.K., Lund S., Baptista M., Panov A.V., Cookson M.R., Greenamyre J.T. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2002, 22:7006-7015.
39. Souza J.M., Giasson B.I., Lee V.M., Ischiropoulos H. Chaperone-like activity of synucleins. FEBS Letters 2000, 474:116-119.
40. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
41. Takeda A., Mallory M., Sundsmo M., Honer W., Hansen L., Masliah E. Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. The American Journal of Pathology 1998, 152:367-372.
42. Tsigelny I.F., Crews L., Desplats P., Shaked G.M., Sharikov Y., Mizuno H., Spencer B., Rockenstein E., Trejo M., Platoshyn O., Yuan J.X., Masliah E. Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS One 2008, 3:e3135.
43. Ueda K., Saitoh T., Mori H. Tissue-dependent alternative splicing of mRNA for NACP, the precursor of non-A beta component of Alzheimer's disease amyloid. Biochemical and Biophysical Research Communications 1994, 205:1366-1372.
44. Winner B., Jappelli R., Maji S.K., Desplats P.A., Boyer L., Aigner S., Hetzer C., Loher T., Vilar M., Campioni S., Tzitzilonis C., Soragni A., Jessberger S., Mira H., Consiglio A., Pham E., Masliah E., Gage F.H., Riek R. In vivo demonstration that alpha-synuclein oligomers are toxic. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:4194-4199.
45. Xia Y., Saitoh T., Ueda K., Tanaka S., Chen X., Hashimoto M., Hsu L., Conrad C., Sundsmo M., Yoshimoto M., Thal L., Katzman R., Masliah E. Characterization of the human alpha-synuclein gene: genomic structure, transcription start site, promoter region and polymorphisms. Journal of Alzheimer's Disease 2001, 3:485-494.